

Imugene attaches an Appendix 3Y – Change of Director’s Interest Notice for Executive Chairman, Mr Paul Hopper

Sydney, Australia, 23 December 2020: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced that Executive Chairman, Mr Paul Hopper, through an associated family entity, has entered into a funding arrangement with an investment bank, which involves a loan facility, cash settled options and stock loans (“**Funding Arrangement**”). The proceeds of the Funding Arrangement are to be used to fund taxation and investment commitments.

The Funding Arrangement has a term of three years and is secured by 107,126,062 fully paid ordinary shares. There are no share price triggers associated with the Funding Arrangement that could result in margin calls or mandatory early repayment.

The ordinary shares provided as security for the Funding Arrangement represent 2.3% of Imugene’s fully paid ordinary shares on issue.

Mr Hopper obtained the necessary approvals pursuant to the company’s ‘Policy for Trading in Company Securities’ prior to entering into the Funding Arrangement.

Mr Hopper said “As the Founder and Executive Chairman of the Company, I am intensely committed to Imugene and I am very excited about its long term prospects. The arrangement relates to a portion of my exposure to Imugene and has become necessary due to my personal circumstances. I see the value of my holding as a whole tied to the future of the company and look forward to continuing to drive success for the company and its shareholders.”

For further information please contact:

Phillip Hains
Company Secretary
T: +61 3 98644839
E: phillip@thecfo.com.au
Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Imugene Limited (ASX:IMU)
ACN:	009 179 551

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	28 November 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Indirect		
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director related entity		
Date of change	22 December 2020		
No. of securities held prior to change		Shares	Options
	Direct	1,248,900	-
	Indirect	175,889,287	25,827,281
	Total	177,138,187	25,827,281
Class	Fully Paid Ordinary Shares (IMU) and Listed Options (IMUOB)		
Number acquired		Shares	Options
	Direct	-	-
	Indirect	827,281	-
	Total	827,281	-
Number disposed		Shares	Options
	Direct	-	-
	Indirect	-	827,281
	Total	-	827,281

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.04 per share	
No. of securities held after change		
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Listed Options	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Mr Hopper has, through an associated family entity, entered into a funding arrangement with Macquarie Bank Limited (“ Funding Arrangement ”)
Nature of interest	The Funding Arrangement includes a loan facility, cash settled options and stock loans referencing 107,126,062 Imugene Limited shares
Name of registered holder (if issued securities)	Moreglade Pty Ltd
Date of change	21 December 2020
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.



The CFO Solution

+ See chapter 19 for defined terms.